Seres Therapeutics (MCRB) Begins Phase 1b Trial of SER-301 for Treatment of Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. USO
5. AMC
6. MSFT
7. AMZN
8. ACN
9. FFAI
10. PAA

Go back to Seres Therapeutics (MCRB) Begins Phase 1b Trial of SER-301 for Treatment of Ulcerative Colitis
(NASDAQ: MCRB) Delayed: 4.06 +0.06 (1.50%)
Previous Close $4.00    52 Week High $44.51 
Open $4.23    52 Week Low $8.05 
Day High $4.33    P/E N/A 
Day Low $4.06    EPS $0.00 
Volume 10,942